(CNN) -The crackdown on off-brand weight loss and diabetes treatment will be applied, so the treatment supply is likely to be strengthened.
The federal deadline for the suspension of sales of GLP-1 drugs arrives this week.
Off -brand products made of complex pharmacies included the same active ingredients such as Ozempic and Wegovy, but there was no approval of food pharmaceutical management.
Many consumers have begun to buy cheap drugs outside the brand when a big tribe occurs when the demand for FDA approval items increases.
A few months ago, the FDA official declared that the tribe was supplemented, so the flexibility provided to the complex drug manufacturer would be terminated.
The Outsourcing Facility Association filed two lawsuits against the FDA for the removal of Tirzepatide and Semaglutide in the list of drug shortages, but the judge allowed the FDA to prohibit the FDA’s plan to maintain a complex product.
Copyright 2025 CNN NEWSOURCE. All rights holdings.
